Comparison 4. Efficacy at 12 months: etanercept + disease‐modifying anti‐rheumatic drug (DMARD) vs. DMARD.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 ACR20	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1 Etanercept 25 mg SC twice weekly	2	958	Risk Ratio (M‐H, Random, 95% CI)	1.20 [1.07, 1.35]
2 ACR50	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 Etanercept 25 mg SC twice weekly	2	958	Risk Ratio (M‐H, Fixed, 95% CI)	1.52 [1.36, 1.70]
3 ACR70	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 Etanercept 25 mg SC twice weekly	2	958	Risk Ratio (M‐H, Fixed, 95% CI)	1.92 [1.59, 2.32]
4 Remission (DAS < 1.6)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Etanercept 25 mg SC twice weekly	1	459	Risk Ratio (M‐H, Fixed, 95% CI)	2.65 [1.85, 3.81]
5 Remission (DAS < 2.6)	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Etanercept 25 mg SC twice weekly	2	987	Risk Ratio (M‐H, Fixed, 95% CI)	1.95 [1.61, 2.35]
6 Change in Total Sharp Score (from baseline)	2	894	Mean Difference (IV, Fixed, 95% CI)	‐2.21 [‐2.99, ‐1.43]
6.1 Etanercept 25 mg SC twice weekly	2	894	Mean Difference (IV, Fixed, 95% CI)	‐2.21 [‐2.99, ‐1.43]
7 Change in Erosion Score (from baseline)	1	418	Mean Difference (IV, Fixed, 95% CI)	‐1.63 [‐2.41, ‐0.85]
7.1 Etanercept 25 mg SC twice weekly	1	418	Mean Difference (IV, Fixed, 95% CI)	‐1.63 [‐2.41, ‐0.85]
8 Change in Joint Space Narrowing Score (from baseline)	1	418	Mean Difference (IV, Fixed, 95% CI)	‐0.67 [‐1.12, ‐0.22]
8.1 Etanercept 25 mg SC twice weekly	1	418	Mean Difference (IV, Fixed, 95% CI)	‐0.67 [‐1.12, ‐0.22]
9 No progression of joint damage (TSS ≤ 0.5)	2	906	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [1.26, 1.51]
9.1 Etanercept 25 mg SC twice weekly	2	906	Risk Ratio (M‐H, Fixed, 95% CI)	1.38 [1.26, 1.51]